Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Strongbridge Biopharma plc (SBBP)
|
|
| Common Size Income Statement |
|
|
|
|
Annual | Quarterly | TTM |
|
| In millions, except per share items | Jun-30-21 | Mar-31-21 | Dec-31-20 | Sep-30-20 | Jun-30-20 | Mar-31-20 | Dec-31-19 | Sep-30-19 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenues | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Cost of goods sold | 5.0% | 5.1% | 7.2% | 9.8% | 13.0% | 16.5% | 17.6% | 19.2% |
| Gross profit | 95.0% | 94.9% | 92.8% | 90.2% | 87.0% | 83.5% | 82.4% | 80.8% |
| Selling, general and administrative | 137.6% | 127.7% | | 146.7% | 174.2% | 197.0% | | 258.4% |
| Research and development | 67.2% | 74.2% | 83.9% | 101.4% | 113.8% | 132.6% | 142.3% | 149.3% |
| General and administrative | | | 37.8% | | | | 55.1% | |
| EBITDA | -109.5% | -106.7% | -123.8% | -157.6% | -200.8% | -245.8% | -285.5% | -1485.6% |
| Depreciation | 0.2% | 0.3% | 0.3% | 0.3% | 0.3% | 0.3% | 0.4% | 0.4% |
| EBITA | -109.7% | -107.0% | -124.1% | -157.9% | -201.1% | -246.1% | -285.9% | -1486.0% |
| Amortization of intangibles | 14.5% | 15.5% | 16.3% | 17.9% | 19.5% | 20.9% | 23.1% | 26.4% |
| EBIT | -124.2% | -122.5% | -140.5% | -175.7% | -220.6% | -267.0% | -309.0% | -1512.3% |
| Pre-tax income | -115.7% | -136.3% | -146.7% | -149.8% | -202.3% | -177.3% | -219.6% | 222.5% |
| Income taxes | 0.0% | 0.0% | 0.0% | 0.0% | 2.7% | 4.5% | 8.1% | 11.2% |
| Net income | -115.7% | -136.2% | -146.7% | -190.3% | -249.3% | -229.2% | -280.2% | 132.1% |
|